Gefitinib Accord

Gefitinib Accord is an oral medication used to treat certain types of cancer. This pharmaceutical is manufactured by Accord Healthcare Polska Sp. Z O.O. and is designed for targeted therapy.

Gefitinib Accord is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific genetic features. It works by targeting and inhibiting the growth of cancer cells. Patients often wonder, 'What is Gefitinib used for?' and the answer lies in its ability to interfere with the epidermal growth factor receptor (EGFR) pathway, which is crucial for cancer cell proliferation.

Common effects of Gefitinib Accord may include skin rash, diarrhea, and fatigue. Some users might experience appetite loss or nausea. These effects can vary in intensity and duration among individuals.

Gefitinib Accord should be handled with care, especially by those with pre-existing medical conditions. It is important to follow the advice of a healthcare professional regarding its use. Pregnant women and individuals with certain allergies should exercise caution.

Gefitinib Accord may interact with other medications, including those that are metabolized by the liver. It is advisable to consult a healthcare provider before combining it with other treatments. Alcohol and certain supplements might also affect its efficacy.